Methylene blue or NAD+?
Two different compounds, two different research questions. Neither should be chosen from a generic promise of more energy.
The short answer
The cited studies do not directly compare these treatments for focus, fatigue or longevity. A mechanism involving cellular metabolism is not enough to declare them interchangeable or rank one above the other.
Side by side
| Methylene blue | NAD+ | |
|---|---|---|
| Clinical evidence cited | Small acute human brain-imaging study | Small IV metabolism pilot |
| Preparation distinction | Approved IV use differs from oral compounded use | IV study differs from the injection and nasal routes here |
| Key question | Evidence and interactions for the exact plan | Evidence for the route and intended outcome |
What the evidence shows
The methylene blue study investigated acute imaging and memory outcomes. The NAD+ pilot followed metabolites during infusion. Neither establishes sustained everyday performance benefits from the products offered here.
Read: Rodriguez et al. Methylene blue and human brain imaging; ProvayBlue prescribing information; Grant et al. NAD+ metabolism during a six-hour IV infusion; FDA: Compounding questions and answers.
What matters for your decision
Methylene blue requires particular attention to serotonergic medicines, certain opioids and G6PD deficiency. Do not interpret the absence of the same interaction warning for NAD+ as proof that its benefits or long-term safety are established. Review each plan on its own merits.
Questions
Can they be stacked?
These sources do not establish that the combination is beneficial or safe for a particular person. Combining different mechanisms is not a substitute for a prescribing decision.
Sources
- Rodriguez et al. Methylene blue and human brain imaging
Radiology, 2016. Small randomized study of acute imaging and memory outcomes.
- ProvayBlue prescribing information
DailyMed. IV methemoglobinemia product; serotonin syndrome and G6PD deficiency warnings.
- Grant et al. NAD+ metabolism during a six-hour IV infusion
Frontiers in Aging Neuroscience, 2019. Small human metabolite pilot, not an energy or recovery efficacy trial.
- FDA: Compounding questions and answers
The distinction between compounded medications and FDA-approved drug products.
